Health Technology Assessment (HTA)
Consumer Consultative Committee Communiqué

The HTA Consumer Consultative Committee (CCC) met on Monday, 12 November 2018. This was the fourth face-to-face meeting for 2018 and two teleconferences have also been held.

Attendees
Attendees included consumer representatives from the Pharmaceutical Advisory Committee (PBAC), the Medical Services Advisory Committee (MSAC), the Prostheses Listing Advisory Committee (PLAC) and their subcommittees, and representatives of the Department of Health. The consumer nominee from the Life Saving Drugs Program Expert Panel, Nicole Millis and guest speaker, Jessica Bean, from the Patient Voice Initiative were also present.

Outcomes
A speaker from the Patient Voice Initiative presented on the importance of improving consumer involvement in HTA processes. Members were invited by the Patient Voice Initiative to present on the involvement of consumers in PBAC, MSAC and PLAC activities at upcoming consumer forums.

There was agreement on the importance of consistent messaging about the role of the CCC and involvement of consumer representatives in the HTA process.

The CCC agreed the following points are achievements and items of interest from the past year:

- Discussions of interest included:
  - out of pocket costs
  - consumer feedback on some of the proposed PBS process improvements
  - the role of consumers in government policy and enquiries (e.g. My Health Record and the Senate Inquiry into Transvaginal Mesh Implants)
  - Consumer representative roles across the different HTA committees
- A training and education workshop was held in May 2018, to share perspectives how consumers provide input to HTA processes
- Ms Watson was invited to be a member of the National HTA Chairs Committee in 2018
- Helped develop plain English Public Summary Documents in conjunction with PBAC.
- The CCC invited a number of guest speakers to present at meetings. The speakers represented a broad spectrum of stakeholders in the HTA process including consumer representatives, out of pockets and internal presenters.
- The CCC invited 3 consumer representative observers from the Advisory Committee on Medicines, the Advisory Committee on Medical Devices and the Life Saving Drugs Program Committee to attend meetings.
- The CCC’s ongoing actions include the following items:
  - To make feedback easier for patients, the CCC is involved in the development of a user friendly PASC Patient survey.
  - The development of a HTA mentoring program.

The next meeting is to be held in February 2019 and will discuss the 2019 work plan for the CCC.